Industrial Pharmaceutical Biotechnology. Heinrich Klefenz
                                  Copyright © 2002 Wiley-VCH Verlag GmbH
                                                    I
                          ISBNs: 3-527-29995-5 (Hardcover); 3-527-60012-4 (Electronic)
       Heinrich Klefenz
       Industrial Pharmaceutical Biotechnology
                            Industrial Pharmaceutical Biotechnology. Heinrich Klefenz
                                  Copyright © 2002 Wiley-VCH Verlag GmbH
                                                   III
                          ISBNs: 3-527-29995-5 (Hardcover); 3-527-60012-4 (Electronic)
       Heinrich Klefenz
       Industrial Pharmaceutical
       Biotechnology
                            Industrial Pharmaceutical Biotechnology. Heinrich Klefenz
                                  Copyright © 2002 Wiley-VCH Verlag GmbH
       IV                 ISBNs: 3-527-29995-5 (Hardcover); 3-527-60012-4 (Electronic)
       Dr. Heinrich Klefenz
       Hauptstr. 35
       D-76879 Bornheim
       Germany
        This book was carefully produced. Nevertheless, author and publisher do not warrant the informa-
        tion contained therein to be free of errors. Readers are advised to keep in mind that statements, data,
        illustrations, procedural details or other items may inadvertently be inaccurate.
       Cover illustration: Design by ‘das trio kommunikation und marketing gmbh; Mannheim, München’
       Copyright of and reprint permissions granted by
       American Society for Microbiology (Tables 7.1, 7.2; ref. 502)
       American Association for the Advancement of Science (Tables: 4.7, ref. 219; 5.1, ref. 224; Figures: 4.1,
       ref. 154; 4.2, ref. 510; 6.1, ref. 301)
       Nature Publishing Group (Fig. 1.3, ref. 432; Tables: 1.6, ref. 432; 1.7, ref. 433; 1.8, ref. 436; 1.9, ref.
       437; 1.10, ref. 439).
       Library of Congress Card No.: Applied for.
       British Library Cataloguing-in-Publication Data:
       A catalogue record for this book
       is available from the British Library
       Die Deutsche Bibliothek Cataloguing-in-Publication Data:
       A catalogue record for this publication is available from Die Deutsche Bibliothek
       ISBN 3-527-29995-5
       © WILEY-VCH Verlag GmbH, Weinheim (Federal Republic of Germany), 2002
       Printed on acid-free paper.
       All rights reserved (including those of translation into other languages). No part of this book may be
       reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated
       into a machine language without written permission from the publishers. Registered names, trademarks,
       etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by
       law.
       Composition: Manuela Treindl, Regensburg
       Printing: Strauss Offsetdruck GmbH, Mörlenbach
       Bookbinding: J. Schäffer GmbH & Co. KG, Grünstadt
       Printed in the Federal Republic of Germany.
                                Industrial Pharmaceutical Biotechnology. Heinrich Klefenz
                                      Copyright © 2002 Wiley-VCH Verlag GmbH
                                                          V
                              ISBNs: 3-527-29995-5 (Hardcover); 3-527-60012-4 (Electronic)
        Preface
        Biotechnology and its applications in medicine, pharma, and related industries represent
                                                           st
        one of the most influential developments and pose one of the greatest challenges of the 21
        century, both with respect to its political, societal, and ethical implications and in the search
        for the fulfillment of its promises for health.
          Biotechnology is stepping beyond previously insurmountable boundaries in understanding
        and manipulating life, in the efforts to understand biology, to eradicate disease, to maintain
        health and vigor, and to endow humans and life forms with desired properties.
          This book aims to describe a fast-moving subject (or rather a whole interconnected sys-
        tem of subjects) and, like in optics, some parts of the picture may be blurred and will
        require further refining. It pulls together topics, which are essential for the realization of
        the promises of biomedicine – the repertoire of genomics, proteomics, cytomics, bio-
        informatics, and the interaction of networks – and combines with pertinent methods in
        nanotechnologies, such as engineering tools to design and construct devices, artificial in-
        telligence and vision processing for nano-devices, implantates, and for the envisioned swarms
        of remedial nano-robots.
          Crucial topics for future therapies are regenerative medicine and the cultivation of tis-
        sues and organs as well as the underlying genetics and regulatory, developmental, bio-
        chemical networks.
          Complex traits, critical in multifactor and degenerative diseases, are being dealt with,
        with a focus on senescence which forms the background against which numerous degen-
        erative and acute diseases develop, the elucidation of which will facilitate the strengthening
        of immune responses, the maintenance of homeostasis and biochemical networks, the pres-
        ervation of the integrity of genetic and cellular structures.
          Drug discovery encompasses the identification of molecular structures, the creation of
        active molecules, and the development of novel comprehensive therapies like immuno-
        therapy and cellular or organismal therapy with genetically engineered cells.
          Biotechnology, chemistry, physics provide the tools for target identification, for the cre-
        ation of new molecular structures, and for the recovery of biologically active molecules
        provided by the biosphere and efficiency-honed during continuous evolutionary processes.
          The huge amounts of data and information alone will not be sufficient to lead to new
        molecular entities and novel therapies, since synthesizing millions of compounds will nei-
        ther fill the universe of potential molecular structures nor allow the identification of those
        three-dimensional structures specifically interacting with targets. The knowledge of the
        biological processes and structures as the templates and targets for the identification of
        active molecules is indispensable.
          Biological plus chemical functional information and knowledge of interactions and net-
        works will be the foundation to which the essential components of creativity and innova-